CSMG Technologies Announces Successful Liver and Spleen Surgery Using Tissue Welding Technology.

CORPUS CHRISTI, Texas -- CSMG Technologies, Inc. (OTCBB:CTUM) announced today 7 cases of ruptured spleen and 8 cases of ruptured liver were repaired during the 1st half of 2005 using tissue welding to seal the liver and spleen tissues without the use of sutures, staples, glues or sealant on the ruptured organ.

Donald S. Robbins, President and CEO of CSMG, said, "The Clinical Hospital N17 in Kiev, Ukraine, trauma treatment center performed the procedures on accident and other trauma victims. The liver and spleen are two of the most difficult organs to treat for rupture. The tissue welding technology group showed shorter surgery time, shorter hospital stays, faster recovery time and almost no blood loss once the organs were sealed."

Prof. A. Makarov, holder of pulmonology chair at the Kiev Medical Academy for Postgraduate Studies said "In the 7 spleen rupture cases the vessels of parenchyma were "welded off" (sealed by welding), which allowed us to save the patient's spleen and avoid a spleenectomy. In the 8 cases of liver ruptures we also achieved hemostasis. In both types of procedures we repaired the organ without use of sutures, staples, glues or sealant."

CSMG owns the technology and exclusive world rights to the medical device for this procedure through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology.

The tissue welding/bonding technology for repair and reconnection of tissue and hollow organs is smokeless, with little heat migration in the tissue. It results in no necrosis and is without the use of foreign matter or conventional wound-closing devices, such as staples, sutures, glues or sealant. The procedures are almost bloodless. Unlike other tissue coagulation methods that tend to destroy tissue by charring, searing and necrosis, the CSMG-patented technology bonds and reconnects incised tissue using a patented low-heat delivery method aimed at restoring the normal functions of the live organs and tissue. The technology leaves little or no scar visible to the naked eye.

About CSMG Technologies' Tissue Welding/Bonding Technology

Surgeons at 10 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials, have completed more than 6,000 human surgeries using more than 70 types of open and laparoscopic surgical procedures and demonstrated that the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecology, fallopian tube, ovary and testicles, and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominal plasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine at Kiev, Ukraine, headed by Professor B.E. Paton. United States and Australia patents have been issued with other U.S. and foreign patents pending.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.ctum.com.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.